MG
MCID: MYS003
MIFTS: 67

Myasthenia Gravis (MG) malady

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Myasthenia Gravis

About this section
Sources:
11Disease Ontology, 13DISEASES, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 35LifeMap Discovery®, 38MedlinePlus, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 49NINDS, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Myasthenia Gravis:

Name: Myasthenia Gravis 35 11 48 25 49 54 27 50 38 39 13 68
Autoimmune Myasthenia Gravis 54
 
Acquired Myasthenia 54
Mg 25

Characteristics:

Orphanet epidemiological data:

54
myasthenia gravis:
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe),1-9/100000 (Worldwide),1-9/1000000 (United States),1-5/10000 (Canada),1-9/100000 (Spain),1-5/10000 (United Kingdom),1-9/100000 (United Kingdom),1-9/100000 (Serbia),1-5/10000 (United States),1-5/10000 (Serbia),1-9/100000 (Italy),1-5/10000 (Austria),1-9/100000 (Australia),1-5/10000 (Italy),1-9/100000 (Taiwan, Province of China),1-5/10000 (Australia),1-9/1000000 (Greece),1-5/10000 (Taiwan, Province of China),1-9/1000000 (Croatia),1-9/100000 (Estonia),1-9/100000 (Greece),1-9/100000 (Croatia),1-9/100000 (Egypt),1-9/1000000 (Worldwide); Age of onset: All ages; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology11 DOID:437
ICD1030 G70.0, G70.00
ICD9CM32 358.0, 358.00
MeSH39 D009157
NCIt45 C60989
Orphanet54 ORPHA589
ICD10 via Orphanet31 G70.0
MESH via Orphanet40 D009157
UMLS via Orphanet69 C0026896

Summaries for Myasthenia Gravis

About this section
NINDS:49 Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal muscles of the body, which are responsble for breathing and moving parts of the body. In myasthenia gravis, the immune system--which normally protects the body from foreign organisms--mistakenly attacks itself.  Symptoms vary in type and intensity. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Certain muscles that control eye and eyelid movements, facial expression, chewing, talking, and swallowing are often, but not always, involved. The muscles that control breathing and neck and limb movements may also be affected. Myasthenia gravis is caused by a defect in the transmission of nerve impulses to muscles. Normally when impulses travel down the nerve, the nerve endings release a neurotransmitter substance called acetylcholine. In myasthenia gravis, antibodies produced by the body's own immune system block, alter, or destroy the receptors for acetylcholine. The first noticeable symptoms of myasthenia gravis may be weakness of the eye muscles, difficulty in swallowing, or slurred speech. Other symptoms may include blurred or double vision, drooping eyelid(s), and weakness in the arms, hands, fingers, legs, and neck. Myasthenia gravis is not directly inherited nor is it contagious.

MalaCards based summary: Myasthenia Gravis, also known as autoimmune myasthenia gravis, is related to hepatitis and autoimmune hemolytic anemia, and has symptoms including back pain, back pain and headache. An important gene associated with Myasthenia Gravis is AKAP12 (A-Kinase Anchoring Protein 12), and among its related pathways are African trypanosomiasis and Malaria. The drugs cyclophosphamide and cyclosporine have been mentioned in the context of this disorder. Affiliated tissues include eye, thymus and skeletal muscle, and related mouse phenotypes are Decreased shRNA abundance (Z-score < -2) and craniofacial.

NIH Rare Diseases:48 Myasthenia gravis (mg) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles of the body. common symptoms include weakness of the muscles that control the eye and eyelid; facial expressions; chewing; talking; and swallowing. weakness tends to increase during periods of activity and improves after periods of rest. myasthenia gravis results from a defect in the transmission of nerve impulses to muscles, due to the presence of antibodies against the acetylcholine. however, the exact cause is unknown. some cases have been linked to tumors in the thymus gland. researchers believe that variations in certain genes may increase a person's risk to develop this condition, but it is likely that other factors also play a role. there is no cure for myasthenia gravis yet, but treatment can significantly improve muscle weakness. some case of myasthenia gravis may go into remission temporarily, and muscle weakness may disappear so that medications can be discontinued. last updated: 2/23/2017

MedlinePlus:38 Myasthenia gravis is a disease that causes weakness in your voluntary muscles. these are the muscles that you control. for example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. you can also have weakness in other muscles. this weakness gets worse with activity, and better with rest. myasthenia gravis is an autoimmune disease. your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. this makes your muscles weaker. other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. with treatment, the muscle weakness often gets much better. medicines can help improve nerve-to-muscle messages and make muscles stronger. other drugs keep your body from making so many abnormal antibodies. these medicines can have major side effects, so they should be used carefully. there are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. sometimes, surgery to take out the thymus gland helps. some people with myasthenia gravis go into remission. this means that they do not have symptoms. the remission is usually temporary, but sometimes it can be permanent. nih: national institute of neurological disorders and stroke

Genetics Home Reference:25 Myasthenia gravis is a disorder that causes weakness of the skeletal muscles, which are muscles that the body uses for movement. The weakness most often starts in the muscles around the eyes, causing drooping of the eyelids (ptosis) and difficulty coordinating eye movements, which results in blurred or double vision. In a form of the disorder called ocular myasthenia, the weakness remains confined to the eye muscles. In most people with myasthenia gravis, however, additional muscles in the face and neck are affected. Affected individuals may have unusual facial expressions, difficulty holding up the head, speech impairment (dysarthria), and chewing and swallowing problems (dysphagia) that may lead to choking, gagging, or drooling.

Wikipedia:71 Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal... more...

Related Diseases for Myasthenia Gravis

About this section

Diseases in the Myasthenia Gravis family:

Myasthenia Gravis Congenital Juvenile Myasthenia Gravis
Adult-Onset Myasthenia Gravis

Diseases related to Myasthenia Gravis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 452)
idRelated DiseaseScoreTop Affiliating Genes
1hepatitis29.9CTLA4, IFNG, IL10, IL2, TNF
2autoimmune hemolytic anemia29.5CTLA4, IFNG, IL2
3exophthalmos29.5IFNG, IL10, IL2, IL4, TNF
4tuberculosis29.5IL10, IL2, IL4, TNF
5rheumatoid arthritis29.0CTLA4, IFNG, IL10, IL2, IL4, TNF
6articulation disorder28.2CTLA4, IFNG, IL10, IL2, IL4, MBP
7juvenile myasthenia gravis12.3
8transient neonatal myasthenia gravis12.3
9adult-onset myasthenia gravis12.3
10neonatal myasthenia gravis12.2
11rippling muscle disease with myasthenia gravis12.2
12myasthenia gravis with thymus hyperplasia12.2
13myasthenia gravis congenital12.1
14myasthenia gravis, limb-girdle12.0
15thymoma11.6
16congenital myasthenic syndrome11.6
17neuromuscular disease11.6
18rippling muscle disease11.4
19paraneoplastic syndromes11.4
20autoimmune oophoritis11.4
21autoimmune polyglandular syndrome type 311.4
22dysphagia11.4
23myasthenic syndrome, congenital, 6, presynaptic11.2
24escobar syndrome11.0
25thymus cancer11.0
26paraneoplastic neurologic disorders11.0
27swallowing disorders11.0
28myasthenic syndrome, congenital, 1011.0
29lambert-eaton myasthenic syndrome10.4
30pyridoxal 5'-phosphate-dependent epilepsy10.3IL10, TNF
31mycobacterium marinum10.3CHRNG, RAPSN
32congenital rubella10.3CHRNE, RAPSN
33pemphigus10.3
34multiple pterygium syndrome, lethal type10.3CHRNA1, CHRNE
35thymic hyperplasia10.3
36mitochondrial complex iii deficiency, nuclear type 210.3CHRNE, MUSK, RAPSN
37steatitis10.3IL2, TNF
38lupus erythematosus10.2
39low anorectal malformation10.2CTLA4, IL10, TNF
40parkinson disease 1110.2IFNG, IL10, TNF
41senile reticular retinal degeneration10.2IFNG, IL10, TNF
42conduct disorder10.2IFNG, IL10, TNF
43pancreatic signet ring cell adenocarcinoma10.2IFNG, IL10, TNF
44pulpitis10.2IFNG, IL10, TNF
45tubular renal disease-cardiomyopathy syndrome10.2IL10, IL4, TNF
46tooth agenesis, selective, 1, with or without orofacial cleft10.2CHRNA1, CHRNG, MUSK, RAPSN
47hereditary alpha tryptasemia syndrome10.2IFNG, IL10, TNF
48rickettsialpox10.2IFNG, IL10, TNF
49lagophthalmos10.2IL10, IL4, TNF
50erb-duchenne and dejerine-klumpke palsies10.2IFNG, IL10, TNF

Graphical network of the top 20 diseases related to Myasthenia Gravis:



Diseases related to myasthenia gravis

Symptoms & Phenotypes for Myasthenia Gravis

About this section

Human phenotypes related to Myasthenia Gravis:

 54 64 (show all 28)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness54 Very frequent (99-80%)
2 ptosis64 54 Frequent (79-30%) HP:0000508
3 ophthalmoparesis64 54 Frequent (79-30%) HP:0000597
4 diplopia64 54 Frequent (79-30%) HP:0000651
5 abnormality of the thymus64 54 Frequent (79-30%) HP:0000777
6 dysarthria64 54 Frequent (79-30%) HP:0001260
7 bulbar palsy64 54 Frequent (79-30%) HP:0001283
8 dysphagia64 54 Frequent (79-30%) HP:0002015
9 dyspnea64 54 Frequent (79-30%) HP:0002094
10 single fiber emg abnormality64 54 Frequent (79-30%) HP:0030006
11 acetylcholine receptor antibody positivity64 54 Frequent (79-30%) HP:0030208
12 muscle specific kinase antibody positivity64 54 Frequent (79-30%) HP:0030210
13 myositis64 54 Frequent (79-30%) HP:0100614
14 hearing impairment64 54 Occasional (29-5%) HP:0000365
15 hyperthyroidism64 54 Occasional (29-5%) HP:0000836
16 hashimoto thyroiditis64 54 Occasional (29-5%) HP:0000872
17 rheumatoid arthritis64 54 Occasional (29-5%) HP:0001370
18 systemic lupus erythematosus64 54 Occasional (29-5%) HP:0002725
19 glycosuria64 54 Occasional (29-5%) HP:0003076
20 paresthesia64 54 Occasional (29-5%) HP:0003401
21 primary adrenal insufficiency64 54 Occasional (29-5%) HP:0008207
22 hyperacusis64 54 Occasional (29-5%) HP:0010780
23 psychosis64 54 Very rare (<4-1%) HP:0000709
24 acrocyanosis64 54 Very rare (<4-1%) HP:0001063
25 seizures64 54 Very rare (<4-1%) HP:0001250
26 hemolytic anemia64 54 Very rare (<4-1%) HP:0001878
27 hepatitis64 54 Very rare (<4-1%) HP:0012115
28 pure red cell aplasia64 54 Very rare (<4-1%) HP:0012410

UMLS symptoms related to Myasthenia Gravis:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, muscle weakness, facial paresis, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00366-A-849.6CHRNA1, RAPSN, TMPO

MGI Mouse Phenotypes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

41 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053829.0ACHE, IFNG, IL10, IL4, RYR1, TNF
2MP:00053708.5AKAP12, CTLA4, IFNG, IL10, IL2, IL4
3MP:00053908.3CHRNA1, CTLA4, IFNG, IL10, IL4, MUSK
4MP:00053918.2ACHE, IFNG, IL10, IL2, IL4, MBP
5MP:00053818.0CTLA4, IFNG, IL10, IL2, IL4, RYR1
6MP:00107717.9CHRNG, CTLA4, IFNG, IL10, IL4, MUSK
7MP:00053697.2ACHE, AGRN, AKAP12, CHRNE, CHRNG, IFNG
8MP:00053976.7ACHE, AKAP12, CTLA4, IFNG, IL10, IL2
9MP:00053766.7ACHE, AGRN, CHRNG, CTLA4, IFNG, IL10
10MP:00036316.4ACHE, AGRN, AKAP12, CHRNA1, CHRNE, CHRNG
11MP:00053866.3ACHE, AGRN, AKAP12, CHRNA1, CHRNE, CHRNG
12MP:00053886.3ACHE, AGRN, AKAP12, CHRNE, CHRNG, CTLA4
13MP:00053786.3ACHE, AGRN, CHRNE, CHRNG, IFNG, IL10
14MP:00107685.4ACHE, AGRN, AKAP12, CHRNA1, CHRNE, CHRNG

Drugs & Therapeutics for Myasthenia Gravis

About this section

Drugs for Myasthenia Gravis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 82)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
AzathioprineapprovedPhase 4, Phase 3177446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
 
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
2
Prednisoneapproved, vet_approvedPhase 4, Phase 3139853-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
3Hormone AntagonistsPhase 4, Phase 313180
4glucocorticoidsPhase 4, Phase 35103
5Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 313168
6Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Early Phase 113086
7HormonesPhase 4, Phase 314415
8Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110956
9AntimetabolitesPhase 4, Phase 3, Phase 212054
10Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 27361
11ImmunoglobulinsPhase 4, Phase 3, Phase 26394
12gamma-GlobulinsPhase 4, Phase 3, Phase 2326
13AntibodiesPhase 4, Phase 3, Phase 26394
14Immunoglobulins, IntravenousPhase 4, Phase 3, Phase 2333
15Rho(D) Immune GlobulinPhase 4, Phase 3, Phase 2326
16Antineoplastic Agents, HormonalPhase 4, Phase 35592
17Anti-Inflammatory AgentsPhase 4, Phase 310729
18
Mycophenolic acidapprovedPhase 395224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
19
Mycophenolate mofetilapproved, investigationalPhase 3952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
20
Leflunomideapproved, investigationalPhase 36775706-12-63899
Synonyms:
210165-51-8
4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl
4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl)
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide
5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide)
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
75706-12-6
A77 1486
AB00052389
AC-6796
AC1L1GYK
AC1Q2EVA
AKOS000265193
AP-501/42475599
Arava
Arava (TN)
Arava, Leflunomide
Aventis Behring Brand of Leflunomide
Aventis Brand of Leflunomide
Aventis Pharma Brand of Leflunomide
BIDD:PXR0189
BPBio1_000930
BRD-K78692225-001-03-9
BSPBio_000844
C045463
C07905
CAS-75706-12-6
CHEBI:6402
CHEMBL960
CID3899
D00749
DB01097
DivK1c_000916
EU-0100649
HMS1570K06
HMS1922M06
HMS2090O12
HMS502N18
HSDB 7289
HWA 486
HWA-486
Hoechst Brand of Leflunomide
I06-2131
IDI1_000916
KBio1_000916
KBio2_000802
KBio2_003370
KBio2_005938
KBioSS_000802
L 5025
L5025_SIGMA
 
LS-86580
Leflunomid
Leflunomida
Leflunomida [INN-Spanish]
Leflunomide
Leflunomide (JAN/USAN/INN)
Leflunomide [USAN:INN]
Leflunomidum
Leflunomidum [INN-Latin]
Lefunomide
Lefunomide [INN-Spanish]
Lefunomide [Inn-Spanish]
Lopac-L-5025
Lopac0_000649
MLS-0003109.0001
MLS000069648
MLS001076267
MolPort-002-345-613
N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide
NCGC00015610-01
NCGC00015610-02
NCGC00015610-03
NCGC00015610-07
NCGC00015610-12
NCGC00022625-03
NCGC00022625-04
NCGC00022625-05
NCGC00022625-06
NCGC00022625-07
NCGC00022625-08
NINDS_000916
NSC677411
Prestwick0_000772
Prestwick1_000772
Prestwick2_000772
Prestwick3_000772
Prestwick_87
RS-34821
S1247_Selleck
SMR000058209
SPBio_002783
SPECTRUM1503927
SU 101
SU 101 (pharmaceutical)
SU-101
SU101
Spectrum5_000850
Spectrum_000322
TL8005179
UNII-G162GK9U4W
ZINC00004840
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-P-toluidide
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
leflunomide
lefunamide
21
BenzocaineapprovedPhase 320161994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
22
rituximabapprovedPhase 3, Phase 1, Phase 21692174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
23
Prednisoloneapproved, vet_approvedPhase 3119350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
24
RocuroniumapprovedPhase 3283119302-91-9, 143558-00-3441290
Synonyms:
(2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane
143558-00-3
AC1L9AWM
BIDD:GT0360
C07556
CHEBI:8884
CID441290
 
DB00728
Esmeron
HMS2090E03
NCGC00167433-01
Rocuronium
Rocuronium bromide
Zemuron
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
25
Tacrolimusapproved, investigationalPhase 31102104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
26
Guaifenesinapproved, vet_approvedPhase 364193-14-13516
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
Amonidren
Amonidrin
Aresol
Benylin-E
Bronchol
Glycerin ether
Glycerin guaiacolate
Glycero-guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
Glyceryl guiacolate
 
Glycerylguaiacol
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesin
Guaifenesine
Guaiphenesin
Guaiphenesine
Guaiphesin
Hustosil
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
O-Methoxyphenyl glyceryl ether
Organidin NR
Pneumomist
Propanosedyl
Reduton
Robitussin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
guaiphenesin
p-Cresyl acetate
27
Methylprednisoloneapproved, vet_approvedPhase 3119383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
28
Aluminum hydroxideapprovedPhase 2, Phase 3, Phase 121021645-51-2
Synonyms:
Al(OH)3
Aluminium hydroxide
Aluminium hydroxide gel, dried
 
Aluminium hydroxide, dried
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
29tannic acidapproved, NutraceuticalPhase 32016
30Cholinergic AgentsPhase 3, Phase 1, Phase 23992
31Anti-Bacterial AgentsPhase 311226
32Antibiotics, AntitubercularPhase 37180
33Neurotransmitter AgentsPhase 3, Phase 1, Phase 218340
34Pyridostigmine BromidePhase 327101-26-8
35Cholinesterase InhibitorsPhase 3592
36Neuromuscular AgentsPhase 31180
37Neuromuscular Blocking AgentsPhase 3429
38Peripheral Nervous System AgentsPhase 323689
39BromidesPhase 3642
40Potassium Channel BlockersPhase 3180
41Neuromuscular Nondepolarizing AgentsPhase 3254
423,4-diaminopyridinePhase 320
43Prednisolone acetatePhase 31193
44Chlorpheniramine, phenylpropanolamine drug combinationPhase 3641
45Methylprednisolone acetatePhase 31193
46Prednisolone hemisuccinatePhase 31193
47Methylprednisolone HemisuccinatePhase 31193
48Calcineurin InhibitorsPhase 31622
49VaccinesPhase 3, Phase 1, Phase 26611
50Prednisolone phosphatePhase 31193

Interventional clinical trials:

(show top 50)    (show all 71)
idNameStatusNCT IDPhase
1Intravenous Immunoglobulin and Plasma Exchange in Myasthenia GravisCompletedNCT01179893Phase 4
2Study Comparing Two Tapering Strategies of Prednisone in Myasthenia GravisActive, not recruitingNCT00987116Phase 4
3The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand ThymectomyUnknown statusNCT01727193Phase 3
4Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia GravisCompletedNCT00306033Phase 3
5Mycophenolate Mofetil in Myasthenia GravisCompletedNCT00285350Phase 3
6Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone TherapyCompletedNCT00294658Phase 3
7Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia GravisCompletedNCT00515450Phase 3
8A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia GravisCompletedNCT01325571Phase 3
9Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)CompletedNCT01997229Phase 3
10FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) PatientsCompletedNCT00309088Phase 3
11A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.CompletedNCT00408213Phase 3
12A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia GravisCompletedNCT00683969Phase 3
13An Open Study for Steroid Resistant, Non-Thymectomized MG PatientsCompletedNCT00309101Phase 3
14A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)CompletedNCT01377922Phase 3
15Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac ArrestCompletedNCT01719770Phase 3
16A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia GravisRecruitingNCT02950155Phase 3
17A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis ExacerbationsRecruitingNCT02413580Phase 3
18A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)RecruitingNCT02774239Phase 3
19Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)RecruitingNCT02970162Phase 3
20ECU-MG-302: An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia GravisActive, not recruitingNCT02301624Phase 3
21A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia GravisNot yet recruitingNCT03165435Phase 2, Phase 3
22Efficacy of Prednisone In the Treatment of Ocular MyastheniaTerminatedNCT00995722Phase 3
23Efficacy of Methotrexate in Myasthenia GravisCompletedNCT00814138Phase 2
24A Pilot Trial of Rituxan in Refractory Myasthenia GravisCompletedNCT00619671Phase 1, Phase 2
25Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia GravisCompletedNCT00774462Phase 2
26The Evaluation of Belimumab in Myasthenia Gravis (MG)CompletedNCT01480596Phase 2
27Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis.RecruitingNCT03052751Phase 2
28Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia GravisRecruitingNCT02565576Phase 2
29Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia GravisRecruitingNCT02100969Phase 2
30A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle WeaknessRecruitingNCT02965573Phase 2
31Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia GravisRecruitingNCT02473965Phase 2
32A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia GravisRecruitingNCT02473952Phase 2
33The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal TumorRecruitingNCT02317224Phase 2
34Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)RecruitingNCT02102594Phase 2
35Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation FailureRecruitingNCT03174964Phase 2
36Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy LossRecruitingNCT03174951Phase 2
37BeatMG: Phase II Trial of Rituximab In Myasthenia GravisActive, not recruitingNCT02110706Phase 2
38Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia GravisActive, not recruitingNCT02609022Phase 1, Phase 2
39Sulfamethoxazole for the Treatment of Primary PREPL DeficiencyEnrolling by invitationNCT02640443Phase 2
40Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia GravisTerminatedNCT00727194Phase 2
41Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia GravisTerminatedNCT01268280Phase 2
42Exercise for Stable Myasthenia GravisRecruitingNCT01047761Phase 1
43Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia GravisTerminatedNCT00424489Phase 1
44A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia GravisUnknown statusNCT01555580Early Phase 1
45Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia GravisUnknown statusNCT00997412
46The Effect of Erythromycin on Occurrence of Leaks From Cervical Esophageal-Gastric Anastomosis After Trans-Hiatal EsophagectomyUnknown statusNCT00373919
47Inherited Myokymia: A Clinical and Genetic Study of a FamilyUnknown statusNCT01250704
48Perception and Multisensory Integration in Neurological Patients Using fMRIUnknown statusNCT01469858
49Therapeutic Plasma Exchange in MGCompletedNCT01927692
50Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-FCompletedNCT02470364

Search NIH Clinical Center for Myasthenia Gravis

Inferred drug relations via UMLS68/NDF-RT46:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myasthenia Gravis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myasthenia Gravis:
Hematopoietic stem cells for refractory myasthenia gravis
Embryonic/Adult Cultured Cells Related to Myasthenia Gravis:
Peripheral blood-derived hematopoietic stem cells


Cochrane evidence based reviews: myasthenia gravis

Genetic Tests for Myasthenia Gravis

About this section

Genetic tests related to Myasthenia Gravis:

id Genetic test Affiliating Genes
1 Myasthenia Gravis27

Anatomical Context for Myasthenia Gravis

About this section

MalaCards organs/tissues related to Myasthenia Gravis:

36
Eye, Thymus, Skeletal muscle, Testes, T cells, B cells, Thyroid

Publications for Myasthenia Gravis

About this section

Articles related to Myasthenia Gravis:

(show top 50)    (show all 1437)
idTitleAuthorsYear
1
Thymectomy and myasthenia gravis: A history of surgical passion and scientific excellence. (28479053)
2017
2
Fatal Morvan Syndrome Associated With Myasthenia Gravis. (28009770)
2017
3
HLA and age of onset in myasthenia gravis. (28495048)
2017
4
Transient neonatal myasthenia gravis due to a mother with ocular onset of anti-muscle specific kinase myasthenia gravis. (28495046)
2017
5
Anesthetic Management of a Patient With Antimuscle-Specific Kinase Antibody-Positive Myasthenia Gravis Undergoing an Open Cholecystectomy: A Case Report. (28079665)
2017
6
Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. (28516329)
2017
7
Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. (28505981)
2017
8
A possible role of low regulatory T cells in anti-acetylcholine receptor antibody positive myasthenia gravis after bone marrow transplantation. (28506261)
2017
9
GVHD-like erythroderma in the clinical course of thymoma-associated myasthenia gravis. (28524043)
2017
10
Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing. (28087666)
2017
11
Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients. (28045063)
2017
12
Validity of Forced Eyelid Closure Test: A Novel Clinical Screening Test for Ocular Myasthenia Gravis. (28492464)
2017
13
Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis. (28494776)
2017
14
Exercise in myasthenia gravis: A feasibility study of aerobic and resistance training. (28085204)
2017
15
Robotic thymectomy for myasthenia gravis with or without thymoma-surgical and neurological outcomes. (28084239)
2017
16
Immature Exosomes Derived from MicroRNA-146a Overexpressing Dendritic Cells Act as Antigen-Specific Therapy for Myasthenia Gravis. (28523463)
2017
17
I^2-Adrenergic receptor gene polymorphisms in the relapse of myasthenia gravis with thymus abnormality. (27338803)
2017
18
Randomized Trial of Thymectomy in Myasthenia Gravis. (28471717)
2017
19
Analysis of mortality and related factors in 2195 adult myasthenia gravis patients in a 10-year follow-up study. (28488612)
2017
20
Frame-shift variant in the CHRNE gene in a juvenile dog with suspected myasthenia gravis-like disease. (28508416)
2017
21
Negative impact of high cumulative glucocorticoid dose on bone metabolism of patients with myasthenia gravis. (28488158)
2017
22
TNFAIP3 gene rs7749323 polymorphism is associated with late onset myasthenia gravis. (28514294)
2017
23
Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis. (28075449)
2017
24
A quantitative method for the assessment of dysarthrophonia in myasthenia gravis. (28477705)
2017
25
Selective or predominant triceps muscle weakness in African-American patients with myasthenia gravis. (28495049)
2017
26
Repetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis. (28516744)
2017
27
Myasthenia Gravis and Its Aeromedical Implications. (28061919)
2017
28
Myasthenia Gravis, Mediastinal Goiter, and Crohn's Disease. (28528037)
2017
29
Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel. (28495138)
2017
30
miR-20b Inhibits T Cell Proliferation and Activation via NFAT Signaling Pathway in Thymoma-Associated Myasthenia Gravis. (27833920)
2016
31
Myasthenia Gravis. (28029925)
2016
32
Response to rituximab in an anti-muscle-specific receptor tyrosine kinase- and anti-acetylcholine recepto-double-positive myasthenia gravis patient concomitant with follicular dendritic cell sarcoma. (26818174)
2016
33
Thymus involvement in myasthenia gravis: Epidemiological and clinical impacts of different self-tolerance breakdown mechanisms. (27609276)
2016
34
Ocular Myasthenia Gravis in Monozygotic Twins with Mirror-image Myopic Anisometropia. (27729761)
2016
35
Temporal deterioration of neurological symptoms and increase of serum acetylcholine receptor antibody levels after thymectomy: a case report of a cat with myasthenia gravis. (27593682)
2016
36
HLA-DRB1*14 and DQB1*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients. (27000234)
2016
37
Gene-Specific Methylation Analysis in Thymomas of Patients with Myasthenia Gravis. (27999265)
2016
38
Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis. (27181991)
2016
39
Curcumin ameliorates experimental autoimmune myasthenia gravis by diverse immune cells. (27181511)
2016
40
Paroxysmal supraventricular tachycardia in anti-musk Myasthenia gravis: A case report. (27653899)
2016
41
Thymoma with Concomitant Pure Red Cell Aplasia, Good's Syndrome and Myasthenia Gravis Responding to Rituximab. (27408396)
2016
42
Myopathic changes detected by quantitative electromyography in patients with MuSK and AChR positive myasthenia gravis. (26778359)
2016
43
Thymectomy for myasthenia gravis: what we know and what we don't. (28066568)
2016
44
Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis. (25962782)
2016
45
Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis. (27170368)
2016
46
Increased frequency of thymic T follicular helper cells in myasthenia gravis patients with thymoma. (27076925)
2016
47
Catastrophes during video-assisted thoracoscopic thymus surgery for myasthenia gravis. (27199379)
2016
48
Analysis of TNF-related apoptosis-inducing ligand and receptors and implications in thymus biology and myasthenia gravis. (28012741)
2016
49
Changes in inflammatory cytokine networks in myasthenia gravis. (27172995)
2016
50
Myasthenia gravis accompanied by Graves' disease, thyrotoxic hypokalemic periodic paralysis and thymic hyperplasia. (27381127)
2016

Variations for Myasthenia Gravis

About this section

Expression for genes affiliated with Myasthenia Gravis

About this section
Search GEO for disease gene expression data for Myasthenia Gravis.

Pathways for genes affiliated with Myasthenia Gravis

About this section

Pathways related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 36)
idSuper pathwaysScoreTop Affiliating Genes
19.6IFNG, IL10, TNF
29.6IFNG, IL10, TNF
39.6AGRN, CHRNA1, MUSK, RAPSN
4
Show member pathways
9.5IFNG, IL2, TNF
59.5IFNG, IL2, TNF
6
Show member pathways
9.5IFNG, IL2, TNF
79.5IFNG, IL2, TNF
89.5IL10, IL4, TNF
99.5IFNG, IL4, TNF
109.4IFNG, IL10, IL2
119.3IFNG, IL2, IL4
129.3IFNG, IL2, IL4
13
Show member pathways
9.2IFNG, IL10, IL2, TNF
149.2IFNG, IL10, IL2, TNF
15
Show member pathways
9.2IFNG, IL10, IL2, TNF
16
Show member pathways
9.2CHRNA1, CHRNE, CHRNG
17
Show member pathways
9.2IFNG, IL10, IL4, TNF
189.1CHRNA1, CHRNE, RYR1
19
Show member pathways
9.1IFNG, IL2, IL4, TNF
20
Show member pathways
9.0IFNG, IL10, IL2, IL4
219.0IFNG, IL10, IL2, IL4
229.0IFNG, IL10, IL2, IL4
239.0CTLA4, IFNG, TNF, TNFSF13B
24
Show member pathways
8.8CTLA4, IFNG, IL2, IL4, TNF
258.8IFNG, IL10, IL2, IL4, TNF
268.8IFNG, IL10, IL2, IL4, TNF
27
Show member pathways
8.8IFNG, IL10, IL2, IL4, TNF
28
Show member pathways
8.8IFNG, IL10, IL2, IL4, TNF
298.8IFNG, IL10, IL2, IL4, TNF
30
Show member pathways
8.8IFNG, IL10, IL2, IL4, TNF
318.6CTLA4, IL10, IL4, TNF, TNFSF13B
32
Show member pathways
8.5CTLA4, IFNG, IL10, IL2, IL4, TNF
338.5IL10, IL2, IL4, TNF, TNFSF13B
348.0IFNG, IL2, IL4, MBP, TNF, TNFSF13B
35
Show member pathways
7.9CTLA4, IFNG, IL10, IL2, IL4, TNF
367.9CTLA4, IFNG, IL10, IL2, IL4, TNF

GO Terms for genes affiliated with Myasthenia Gravis

About this section

Cellular components related to Myasthenia Gravis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1neuromuscular junctionGO:003159410.4ACHE, CHRNA1, MUSK, RAPSN
2external side of plasma membraneGO:000989710.0CTLA4, IFNG, IL4, TNF
3acetylcholine-gated channel complexGO:000589210.0CHRNA1, CHRNE, CHRNG
4postsynaptic membraneGO:00452119.4CHRNA1, CHRNE, CHRNG, MUSK, RAPSN
5cell junctionGO:00300549.1ACHE, AGRN, CHRNA1, CHRNE, CHRNG, MUSK
6synapseGO:00452028.2ACHE, AGRN, CHRNA1, CHRNE, CHRNG, MUSK
7extracellular regionGO:00055768.2ACHE, AGRN, IFNG, IL10, IL2, IL4
8plasma membraneGO:00058866.8ACHE, AGRN, AKAP12, CHRNA1, CHRNE, CHRNG

Biological processes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 31)
idNameGO IDScoreTop Affiliating Genes
1endothelial cell apoptotic processGO:007257710.6IL10, TNF
2negative regulation of cytokine secretion involved in immune responseGO:000274010.6IL10, TNF
3positive regulation of heterotypic cell-cell adhesionGO:003411610.6IL10, TNF
4positive regulation of calcidiol 1-monooxygenase activityGO:006055910.5IFNG, TNF
5skeletal muscle acetylcholine-gated channel clusteringGO:007134010.5MUSK, RAPSN
6receptor biosynthetic processGO:003280010.5IL10, TNF
7positive regulation of mononuclear cell migrationGO:007167710.5IL4, TNF
8positive regulation of vitamin D biosynthetic processGO:006055710.5IFNG, TNF
9negative regulation of nitric oxide biosynthetic processGO:004501910.4IL10, IL4
10negative regulation of T-helper 17 cell differentiationGO:200032010.3IL2, IL4
11regulation of isotype switchingGO:004519110.3IL10, IL4
12negative regulation of heterotypic cell-cell adhesionGO:003411510.3IL10, MBP
13negative regulation of growth of symbiont in hostGO:004413010.2IFNG, IL10, TNF
14B cell costimulationGO:003129610.2IL4, TNFSF13B
15positive regulation of chemokine biosynthetic processGO:004508010.1IFNG, IL4, TNF
16defense response to protozoanGO:004283210.1IFNG, IL10, IL4
17positive regulation of MHC class II biosynthetic processGO:004534810.0IFNG, IL10, IL4
18positive regulation of isotype switching to IgG isotypesGO:004830410.0IFNG, IL2, IL4
19positive regulation of tyrosine phosphorylation of STAT proteinGO:00425319.9IFNG, IL2, IL4
20cation transmembrane transportGO:00986559.9CHRNA1, CHRNE, CHRNG
21excitatory postsynaptic potentialGO:00600799.9CHRNA1, CHRNE, CHRNG
22neuromuscular synaptic transmissionGO:00072749.8CHRNA1, CHRNE, CHRNG
23type 2 immune responseGO:00420929.7IL10, IL4
24positive regulation of B cell proliferationGO:00308909.7IL2, IL4, TNFSF13B
25regulation of postsynaptic membrane potentialGO:00600789.7CHRNA1, CHRNE, CHRNG
26response to nicotineGO:00350949.6CHRNA1, CHRNE, CHRNG
27muscle contractionGO:00069369.6CHRNE, CHRNG, RYR1, TTN
28positive regulation of protein phosphorylationGO:00019349.5IFNG, IL2, IL4, MUSK, TNF
29positive regulation of T cell proliferationGO:00421029.3IFNG, IL2, IL4, TNFSF13B
30synaptic transmission, cholinergicGO:00072719.1CHRNA1, CHRNE, CHRNG, RAPSN
31immune responseGO:00069558.1CTLA4, IFNG, IL10, IL2, IL4, MBP

Molecular functions related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1acetylcholine receptor activityGO:00154649.8CHRNA1, CHRNE, CHRNG
2acetylcholine-gated cation-selective channel activityGO:00228489.8CHRNA1, CHRNE, CHRNG
3extracellular ligand-gated ion channel activityGO:00052309.7CHRNA1, CHRNE, CHRNG
4ligand-gated ion channel activityGO:00152769.7CHRNA1, CHRNE, CHRNG
5acetylcholine bindingGO:00421669.6ACHE, CHRNA1, CHRNE, CHRNG
6protease bindingGO:00020209.2MBP, RYR1, TNF, TTN
7cytokine activityGO:00051258.7IFNG, IL10, IL2, IL4, TNF, TNFSF13B

Sources for Myasthenia Gravis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet